The report forecasts the global epilepsy drugs market to grow at a CAGR of 4.45% during the period 2016-2020.
Epilepsy is characterized by recurrent seizures caused by the improper balance between inhibitory and excitatory signals in the brain. The symptoms of epilepsy, caused by brain malformations and tumors, birth trauma, and high-risk pregnancies, can be benign or life-threatening. A majority of epilepsy cases have an unknown etiology.
The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
A trend which will boost market growth is the reformulation of marketed drugs. Drug delivery systems such as dispersible and film-coated tablets increase the efficacy of medicines either by increasing the bio-availability of the drug or by expanding patient compliance. This reformulation results in products with improved safety and efficacy profiles and provides an opportunity for drug manufacturers to extend the term of their drug's patents, delaying the market entry of generics.
According to the report, a key growth driver is the tentative approval of late-stage pipeline molecules. Though a number of branded and generic drugs are available in the market to treat epilepsy, they provide only symptomatic treatment. Hence, the need for effective medications still prevails in the market. This has increased investment in the R&D of new drugs for epilepsy by companies such as Marinus Pharmaceuticals, SAGE Therapeutics, H. Lundbeck, and CURx Pharmaceuticals.
Further, the report states that one challenge that could hamper market growth is the social stigma associated with epilepsy.
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Pipeline analysis
PART 06: Key buying criteria for anti-epileptic drugs
PART 07: Market landscape
PART 08: Market segmentation by generation of drugs
PART 09: Market segmentation by spectrum of activity